Clinical Trials Sponsored by Suzhou BlueHorse Therapeutics Co., Ltd.

Total 767 results

Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Solid Tumor

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Cervical Carcinoma

China
Suzhou Transcenta Therapeutics Co., Ltd.

Not yet recruiting

Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Cancer | Advanced Cancer | Gastroesophageal-junction Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, China
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

A Study of MSB0254 Injection in Advanced Solid Tumors

Advanced Solid Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Not yet recruiting

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Advanced Solid Tumors

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Suzhou Transcenta Therapeutics Co., Ltd.

Recruiting

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Colorectal Adenocarcinoma | Locally Advanced Solid Tumor | Metastatic Tumor

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States, China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Cancers | Metastatic Human Papillomavirus-Related Malignant Neoplasm

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Not yet recruiting

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Locally Advanced or Metastatic Breast Cancer

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid Tumors

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study YL201 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.
Hoffmann-La Roche

Recruiting

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Recruiting

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Cancer | Advanced Cancer | Gastroesophageal-junction Cancer

United States
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Recruiting

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Advanced Cancer

China
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Knee Arthroplasty, Total

China
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Suzhou Kerui Medical Technology Co., Ltd
Suzhou Mingshi Optical Technology Co., Ltd

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Defocusing Lenses in Delaying Myopia Progression

Myopia

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Trial of SHR-4849 in Advanced Solid Tumors

Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
3H (Suzhou) Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Solid Tumors With FGFR2 Alterations, Adult

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumor

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Asthma | Healthy Participants

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Ovarian Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

Healthy Participants

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

Psoriasis

China
Suzhou Neologics Bioscience Co., Ltd.

Not yet recruiting

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Ankylosing Spondylitis

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Breast Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Safety and Tolerability Study of Jaktinib

Myelofibrosis

United States

Clinical Trials Sponsored by Suzhou BlueHorse Therapeutics Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations